Anna Azvolinsky, PhD

OncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.

OncLive spoke with Lisa A. Carey, MD, professor at the University of North Carolina Chapel Hill, about recent developments for patients with triple-negative breast cancer.

The second-generation oral ALK inhibitor ceritinib (Zykadia; LDK378) demonstrated rapid and durable responses in patients with ALK-positive, metastatic, non–small cell lung cancer (NSCLC)-regardless of whether they had been previously treated with crizotinib-achieving overall response rates of 60% or more in each subgroup of patients who had received zero to three prior therapies for their advanced lung cancer.

One-third (30%) of chemotherapy-naïve non–small cell lung cancer (NSCLC) patients treated with nivolumab, an anti-PD-1 immune checkpoint antibody, responded to treatment in a phase I study.

Researchers are making progress in identifying biomarkers and developing assays that will help clinicians improve the management of patients with prostate cancer from screening strategies to making therapy choices

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Lymphoma expert Andre Goy, MD, provides insight into the rapidly changing treatment landscape for patients with mantle cell lymphoma.

The role of allogeneic transplant in the treatment of adult patients with acute lymphoblastic leukemia (ALL) is evolving as a result of new studies providing evidence of the efficacy of an improved chemotherapy regimen

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the management of CRPC.

In the last decade, there have been tremendous improvements in the treatment of HER2-positive breast cancer with new HER2-targeted agents improving survival in both the adjuvant and metastatic settings.

During the past decade, several oral tyrosine kinase inhibitors targeting the vascular endothelial growth factor have been approved for the first-line treatment of metastatic renal cell carcinoma.

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

With seven targeted therapies approved for metastatic renal cell carcinoma, researchers and drug developers are now focusing on understanding the best way to sequence these therapies and on identifying predictive biomarkers of response.

Next-generation ALK inhibitors are being developed to address the unmet need of patients with non-small cell lung cancer who are becoming resistant to crizotinib.

While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.

A two-step immunotherapy approach consisting of adoptive T-cell therapy and a dendritic cell vaccine has shown activity in a phase I advanced ovarian cancer clinical trial.

Clinical trials are under way that may change the way risk of recurrence is assessed for early-stage breast cancer patients, allowing for individualization of therapy.

The treatment of late-stage prostate cancer is shifting; with the approval of two new oral agents there are now more options for men with metastatic prostate cancer then just two years ago.

Three prominent breast cancer clinicians and researchers share their opinions on adjuvant anthracyclines, fluoropyrimidines, and taxane agents for women with early breast cancer.

J. Michael Dixon, MBChB, MD, and Patrick I. Borgen, MD, discuss the pros and cons of long-term clinical follow-up care of patients with breast cancer.